Giang Minh Vu

Giang Minh Vu

Auto-generated profile, based on publicly available information

Giang Minh Vu

Center for Biomedical Informatics Vingroup Big Data Institute Hanoi Vietnam

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2024 in Heliyon
Verified
Journal Article
Open access
TNThien Khac Nguyen
Thien Khac Nguyen
GVGiang Minh Vu
Giang Minh Vu
VDVinh Chi Duong
Vinh Chi Duong
TPThang Luong Pham
Thang Luong Pham
NNNguyen Thanh Nguyen
Nguyen Thanh Nguyen
THTham Hong Hoang
Tham Hong Hoang
Despite the raised awareness of the role of pharmacogenomic (PGx) in personalized medicines for COVID-19, data for COVID-19 drugs is extremely scarce and not even a publication on this topic for post-COVID-19 medications to date. In the current study, we investigated the genetic variations associated with COVID-19 and post-COVID-19 therapies by using whole genome sequencing data of the 1000 Vietnamese Genomes Project (1KVG) in comparison with other populations retrieved from the 1000 Genomes Project Phase 3 (1KGP3) and the Genome Aggregation Database (gnomAD). Moreover, we also evaluated the risk of drug interactions in comorbid COVID-19 and post-COVID-19 patients based on pharmacogenomic profiles of drugs using a computational approach. For COVID-19 therapies, variants related to the response of two causal treatment agents (tolicizumab and ritonavir) and antithrombotic drugs are common in the Vietnamese cohort. Regarding post-COVID-19, drugs for mental manipulations possess the highest number of clinical annotated variants carried by Vietnamese individuals. Among the superpopulations, East Asian populations shared the most similar genetic structure with the Vietnamese population, whereas the African population showed the most difference. Comorbid patients are at an increased drug-drug interaction (DDI) risk when suffering from COVID-19 and after recovering as well due to a large number of potential DDIs which have been identified. Our results presented the population-specific understanding of the pharmacogenomic aspect of COVID-19 and post-COVID-19 therapy to optimize therapeutic outcomes and promote personalized medicine strategy. We also partly clarified the higher risk in COVID-19 patients with underlying conditions by assessing the potential drug interactions.

9 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SNSang Nguyen
Sang Nguyen
TPTien Pham
Tien Pham
THTham Hong Hoang
Tham Hong Hoang
TTTrang Tran
Trang Tran
GVGiang Vu
Giang Vu
NVNam Sy Vo
Nam Sy Vo
Polygenic risk scores (PRS) represent the cumulative impact of numerous common genomic variants, to predict clinical phenotypes and outcomes for individuals. However, PRS are typically derived from GWAS for populations of European origin, often resulting in reduced performance and their transferability to other underserved populations. In this study, we comprehensively analyzed 550 samples for nine common diseases in the Vietnamese population, including breast cancer (BC), colorectal cancer (CRC), gastric cancer (GC), chronic kidney disease (CKD), coronary artery disease (CAD), hyperlipidemia, osteoporosis, osteoarthritis, and Parkinson’s disease (PD). Healthy control subjects were taken from the 1000 Vietnamese Genomes Project (VN1K). We evaluated seven advanced PRS algorithms using multiple GWAS datasets from both East Asian and European populations and identified the best performing method for each disease. PRS accuracy, assessed by incremental liability R-squared (incR2), ranged from 1.8% in CKD to 8.3% in CAD. The Area Under the Curve (AUC) ranged from 0.55 for CKD to 0.70 for CAD. Integrating with transcriptional risk scores (TRS), the PRS+TRS model led to a consistently increased incR2 across all nine diseases ranging from 1% to 15%. These findings offer valuable insights into the implementation of PRS+TRS for disease risk prediction in the Vietnamese population, where a similar approach would be applicable to other underrepresented populations.